Company intelligence / Profile preview

Shuttle Diagnostics

Gaithersburg, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Shuttle Diagnostics is developing advanced diagnostic and theranostic platforms for prostate cancer, most notably PC-Rad (predictive blood test for radiation therapy outcomes in localized disease) and PSMA-B ligand (boron-containing small molecule with nanomolar PSMA affinity, under preclinical evaluation for PET imaging, therapeutic, and sensitizer applications). Provisional patent filed for PSMA-targeted PARP inhibitor conjugates for precision therapy. No clinical results available yet; current focus is on preclinical validation and sponsored research with UCSF.[1][2][4][5][6][7][8]

Therapeutic areas: Oncology
Modalities: Small moleculeRadiopharmaceuticalBiologic
Industry: Biotech

Partnerships

University of California, San Francisco (UCSF)

Beyond the preview

Go deeper on Shuttle Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shuttle Diagnostics.

Explore the full profile